132 related articles for article (PubMed ID: 32270727)
21. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
22. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Li M; Li Y; Yin Q; Mi R; Chen L; Du J; Wei X
Leuk Lymphoma; 2014 Jul; 55(7):1578-83. PubMed ID: 24070424
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
[TBL] [Abstract][Full Text] [Related]
24. Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis.
Borchmann P; Heger JM; Mahlich J; Papadimitrious MS; Riou S; Werner B
Oncol Ther; 2023 Mar; 11(1):65-81. PubMed ID: 36447041
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
[TBL] [Abstract][Full Text] [Related]
26. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
27. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
[TBL] [Abstract][Full Text] [Related]
29. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
30. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
32. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
34. Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.
Tsutsué S; Makita S; Yi J; Crawford B
Future Oncol; 2021 Nov; 17(33):4511-4525. PubMed ID: 34414783
[No Abstract] [Full Text] [Related]
35. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
36. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis.
Tsutsué S; Makita S; Yi J; Crawford B
PLoS One; 2022; 17(5):e0269169. PubMed ID: 35622820
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
[TBL] [Abstract][Full Text] [Related]
38. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
40. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]